Fig. 3

Mean healthcare costs in first and second year of life—cCMV_21-S versus "healthy" controls. (*) Drugs include costs of outpatient pharmaceuticals; costs of inpatient pharmaceuticals are included in inpatient costs. Incremental costs are shown with respective p-values. P-value < 0.05 was considered as statistically significant (Wilcoxon rank-sum test). Figures were commercially rounded, which may result in minor calculation differences. cCMV congenital cytomegalovirus, cCMV_21-S infants with inpatient cCMV diagnosis and symptoms during the first 21 days of life, “Healthy” infants with no ICD-10-GM diagnosis (except Z-diagnoses) until 4th preventive health checkup (U4) and no cCMV or CMV diagnosis in the observation period